Immunology and Microbiology
T Cell
100%
Immunotherapy
68%
Chimeric Antigen Receptor T-Cell
62%
CD19
61%
B Cell
53%
Immune Response
51%
Intravenous Immunoglobulin
51%
Agonist
45%
Mouse
40%
Programmed Death-Ligand 1
39%
Dendritic Cell
34%
Lymphocyte Count
34%
Toll-Like Receptor
34%
Rituximab
34%
Obinutuzumab
34%
Immunosuppressive Drug
29%
Chimeric Antigen Receptor
25%
Overall Survival
25%
TLR7
22%
T-Helper Cell
22%
Antigen Presentation
22%
CD20
22%
Immunity
21%
Cell Death
20%
Mouse Model
19%
Syngenic
18%
Natural Killer Cell
17%
Interleukin 12
17%
Escherichia Coli Vaccine
17%
MHC Class I
17%
Actin
17%
Bacilli
17%
Eotaxin 2
17%
Mycobacterium bovis
17%
Oropharynx
17%
Cell Activation
17%
Lymphoma Cell
17%
Cancer Antibody
17%
Antigen-Presenting Cell
17%
Lysosome
17%
Carcinoembryonic Antigen
17%
Cytokine
17%
Cell Activity
17%
CCR2
17%
Tumor Cell
16%
Low Drug Dose
14%
Vaccine Efficacy
12%
Monoclonal Antibody
11%
Immune Checkpoint Blockade
11%
Secretion (Process)
9%
Medicine and Dentistry
Radiation Therapy
89%
Neoplasm
68%
Chimeric Antigen Receptor T-Cell
51%
T Cell
40%
Ovarian Cancer
34%
Oropharyngeal Cancer
34%
Lymphocyte
34%
Overall Survival
25%
Solid Malignant Neoplasm
24%
Hazard Ratio
21%
B-Cell Lymphoma
20%
Programmed Death-Ligand 1
20%
Immunotherapy
19%
Tumor Antigen
19%
Toll Like Receptor 7
17%
Cytokine
17%
Tumor Model
17%
Tumor Microenvironment
17%
Tumor Infiltrating Lymphocyte
17%
Cisplatin
17%
Cyclophosphamide
17%
Cancer Cell
17%
Chimeric Antigen Receptor T-Cell Immunotherapy
17%
Ex Vivo
17%
Gastrointestinal Toxicity
17%
Interleukin 17
17%
Malignant Neoplasm
16%
Immune Response
15%
Chimeric Antigen Receptor
15%
Immunocompetent Cell
15%
Ovarian Tumor
11%
Tumor Cell
10%
Krukenberg Tumor
9%
Oropharynx Squamous Cell Carcinoma
8%
Lymphoid Cell
8%
RNA Sequence
8%
Intestinal Permeability
8%
Pelvis Cancer
8%
Cytokine Production
8%
Intestinal Mucosal Barrier
8%
Chemokine
8%
Immunity
8%
Gamma Chemokine
8%
Tissue Injury
8%
Flow Cytometry
8%
Chemokine Receptor
8%
Low Drug Dose
7%
Secretion (Process)
7%
CAR T-cell therapy
6%
Autologous Tumor Cell
6%
Pharmacology, Toxicology and Pharmaceutical Science
Neoplasm
74%
Obinutuzumab
34%
Chemotherapy
28%
Rituximab
27%
Malignant Neoplasm
27%
B Cell Lymphoma
26%
Cytokine
25%
Immunotherapy
18%
Actin
17%
Solid Malignant Neoplasm
17%
Chimeric Antigen Receptor
17%
Cyclophosphamide
17%
Oropharynx Cancer
17%
Carcinoembryonic Antigen
17%
Toll Like Receptor 7
17%
Ovary Cancer
17%
MedImmune
17%
Programmed Death 1 Receptor
17%
Tumor Microenvironment
17%
Hexametaphosphate Sodium
17%
Tumor Model
17%
Interleukin 17
17%
Gastrointestinal Toxicity
17%
Mouse
15%
Overall Survival
14%
Immunoglobulin
14%
CD19 Antigen
13%
CD8 Antigen
11%
Receptor
11%
Programmed Cell Death
10%
Chronic Lymphatic Leukemia
9%
Cisplatin
9%
Combination Therapy
9%
Immune Checkpoint Inhibitor
8%
Pelvis Cancer
8%
Gamma Chemokine
8%
Tissue Injury
8%
Intestinal Permeability
8%
Flow Cytometry
8%
Chemokine
8%
Chemokine Receptor
8%
RNA-Sequencing
8%
Melanoma
5%
Acute Lymphoblastic Leukemia
5%
Recombinant Antibody
5%
Dendritic Cell Vaccine
5%
Virus Vaccine
5%
Ipilimumab
5%
T Lymphocyte Receptor
5%
Immunosuppressive Agent
5%
